NCT06996119
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
At risk: Primary completion moved at least 1 year 5 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from May 25, 2027 to Nov 5, 2028
- Eligibility criteria expanded, about 42 words
- Secondary endpoints: details revised at 8 of 12 entries
- Study description revised
- Minor Start date changed from estimate of May 25, 2026 to Jun 12, 2026v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
Patients receive fludarabine IV on days -7 to -3 and melphalan IV over 1 hour on day -2 or busulfan IV on days -7 and -6 and fludarabine IV on days -7 to -2. Patients receive HCT infusion on day 0 per institutional standards of practice. Patients also receive emapalumab IV over 1 hour on days -8. -1, -7, 14 and 21, cyclophosphamide IV on days 3 and 4, tacrolimus IV or PO on days 5-95, mycophenolate mofetil IV or PO on days 5-35. Additionally, patients undergo chest CT and ECHO or MUGA at baseline and blood sample collection throughout the study.
Procedures: Biospecimen Collection, Computed Tomography, Echocardiography Test, Hematopoietic Cell Transplantation, Multigated Acquisition Scan
Drugs: Busulfan, Cyclophosphamide, Fludarabine, Melphalan, Mycophenolate Mofetil, Tacrolimus
Biologicals: Emapalumab
Other: Questionnaire Administration
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States